Immediate Impact
64 standout
Citing Papers
Enhancing immunotherapy with tumour-responsive nanomaterials
2025 Standout
Harnessing innate immune pathways for therapeutic advancement in cancer
2024 Standout
Works of Alice Bexon being referenced
A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation
2022
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
2014
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Alice Bexon | 198 | 58 | 101 | 280 | 197 | 46 | 598 | |
| Katsushi Hiramatsu | 126 | 24 | 128 | 355 | 302 | 58 | 735 | |
| Hiroyuki Fuke | 109 | 36 | 67 | 288 | 143 | 38 | 726 | |
| Colette Chapuis‐Cellier | 152 | 23 | 38 | 97 | 61 | 40 | 588 | |
| Chung-Bao Hsieh | 119 | 22 | 107 | 287 | 257 | 50 | 667 | |
| T Matsuno | 156 | 15 | 36 | 81 | 227 | 53 | 524 | |
| Jinpiao Lin | 134 | 26 | 40 | 231 | 41 | 32 | 668 | |
| Vijay Subramanian | 98 | 21 | 66 | 143 | 313 | 41 | 739 | |
| Toshihiko Kōji | 110 | 74 | 59 | 271 | 97 | 36 | 666 | |
| Mami Kanamoto | 271 | 35 | 130 | 238 | 248 | 43 | 702 | |
| Yoshihiro Aiba | 67 | 49 | 25 | 181 | 111 | 36 | 598 |
All Works
Loading papers...